Ventfort
Blood vessel peptide extract in capsule form, taken in monthly courses for vascular and circulatory support - the extract counterpart to the synthetic tripeptide Vesugen.
Also known as A-3, vascular Cytomax, blood vessel peptide bioregulator, Ventfort A-3, Ventfort, Ventfort Lingual, A-3
Anecdotal — Community reports without controlled evidence. Treat the confident dosing charts accordingly.
No controlled human trials exist for Ventfort. The supporting material is manufacturer literature plus Russian preclinical work on vascular peptide fractions. Treat any cardiovascular claim made for this capsule as unsupported.
How it works
Ventfort is peptide complex A-3, extracted from the vascular tissue of young calves at 10 mg per capsule. The claimed action is improvement in endothelial cell function, microcirculation and capillary permeability, framed through the same gene-de-repression argument as the rest of the line. Its synthetic counterpart is Vesugen (Lys-Glu-Asp). Neither the extract nor the synthetic has a human vascular endpoint study - no flow-mediated dilation, no blood pressure trial, no carotid intima-media thickness data.
Targets: Vascular endothelium, Microcirculation, Capillary permeability
Dosing
| Protocol | Dose | Frequency | Route |
|---|---|---|---|
| Standard capsule course10-15 minutes before a meal. | 10 mg – 20 mg | one to two capsules daily for 10 to 30 days | oral |
- · 10 mg of peptide complex per capsule.
Cycling
Ten to thirty days per course, two to three courses a year.
Pharmacology
- Half-life
- Not measured after oral dosing.
- Onset
- Nothing acute. Claims are framed over a full monthly course.
- Routes
- oral, sublingual
- Molecule
- Bovine vascular tissue-derived peptide complex in capsule form
Handling
- Diluent
- Not applicable - supplied as oral capsules.
- Lyophilised
- Not applicable - store capsules cool, dry and out of direct sunlight.
- Reconstituted
- Not applicable.
- Light sensitive
- Yes — keep it out of the light
Mixing
Nothing to reconstitute.
Side effects
- uncommonMild digestive upset— Often excipient-related.
- rareAllergic reaction to bovine protein— Animal-tissue-derived product.
Do not use if
- Do not substitute this for antihypertensive, statin or anticoagulant therapy - that substitution is the actual risk with vascular bioregulators.
- Known bovine protein allergy.
- Pregnancy and breastfeeding - no data.
- Active malignancy, given the angiogenic framing of the claims.
Combining it
- redundantvesugen — Vesugen is the synthetic tripeptide counterpart; running both is duplication.
- synergychelohart — Vessel plus heart is the standard Russian cardiovascular Cytomax pairing.
What to monitor
- · Blood pressure logged consistently before, during and after a course.
- · A lipid panel and hs-CRP if this is part of a cardiovascular protocol.
Legal status
Sold as a food supplement in Russia and much of Europe; imported elsewhere as a dietary supplement. Not an approved drug.
References
- Khavinson & Malinin, Gerontological Aspects of Genome Peptide Regulation (Karger monograph) (review)
Mechanism in depth
No primary literature exists for Ventfort - a PubMed search for the brand returns nothing - so the mechanistic content is entirely borrowed from Vesugen, the synthetic Lys-Glu-Asp tripeptide, and that record carries the detail. The relevant part is what the KED work actually showed: normalisation of endothelin-1 expression in atherosclerotic and restenotic endothelium, restoration of connexin-mediated cell-cell communication, and increased sirtuin-1 expression. All in vitro, all with a defined molecule applied directly to cells. Ventfort is an undefined bovine vascular extract swallowed as a capsule. It shares the tissue of origin and the marketing, not the data. There is a further point worth making about the whole vascular sub-line: endothelial dysfunction is measurable in humans. Flow-mediated dilation of the brachial artery is a standard, non-invasive, decades-old technique. Reactive hyperaemia peripheral arterial tonometry is commercially available. Circulating endothelin-1 can be assayed. Any of these could have been used to test a vascular bioregulator in fifty people over a month at modest cost. None has been. That absence, for a product line marketed on vascular health since the 1990s, is itself information.
What usually goes wrong
Substitution, and it is the reason this product deserves more scepticism than the harmless ones. Hypertension and hyperlipidaemia are silent, so a person can feel entirely well while running capsule courses instead of treatment and accumulating arterial damage for years. Nothing here has been shown to change any vascular measurement in a human being. The angiogenic framing also cuts the wrong way in anyone with an active malignancy or proliferative retinopathy, though with an unabsorbed extract that concern is largely theoretical. And the bovine-source caution applies as everywhere in this line.
Bloodwork worth running
| Marker | When | Why it matters |
|---|---|---|
| ApoB, and Lp(a) once in your life | Baseline. Lp(a) is largely genetically determined and needs testing only once. | These are the actual causal drivers of atherosclerotic disease, and ApoB is a better risk marker than LDL cholesterol because it counts particles. If you are spending money on vascular health, spend it here first.Act if: ApoB above roughly 100 mg/dL with cardiovascular risk, or Lp(a) above 50 mg/dL, means evidence-based lipid lowering. Nothing in this capsule substitutes for that. |
| hs-CRP | Baseline and six weeks after a course, away from infection or hard training. | The cheap inflammatory marker with genuine cardiovascular risk data behind it, and the only routine test with a plausible mechanistic link to what this product claims.Act if: Persistently above 3 mg/L is a risk signal that deserves proper attention rather than a peptide course. |
| Seven-day home blood pressure average, morning and evening | Seven days before the course and seven days starting two weeks after it ends, same cuff, same arm, same time. | Not bloodwork, but the cheapest objective vascular measure that exists and the one an endothelin-1 mechanism would predict. Clinic readings are too noisy to detect anything.Act if: A home average above 135/85 mmHg is hypertension and needs treating. Do not stop or reduce antihypertensives because a capsule course is running. |
Pharmacokinetics
- Metabolism
- Presumed near-complete gastrointestinal proteolysis.
- Elimination
- Not characterised.
Receptor targets
- No identified receptor or molecular target — None published
Nothing has been characterised for this preparation.
- Vascular endothelium, microcirculation and capillary permeability (claimed)
Manufacturer claim, inherited by analogy from the in vitro Vesugen work. Not demonstrated for this product or this route.
What to expect, and when
Nothing acute and nothing perceptible at any point - endothelial function is asymptomatic by nature. Weeks one to four: no expected change. Six weeks after a course: the only window where a blood pressure average or hs-CRP retest carries information, and no change is the honest expectation. There is no timepoint at which this product has been shown to do anything.
Stacking and comparisons
Ventfort with Vesugen is duplication across formats; the synthetic has the data such as it is. Ventfort with Chelohart is the vessel-plus-heart Cytomax pairing and is the intended architecture of the product line rather than a tested protocol. If cardiovascular health is genuinely the goal, the stack with outcome data behind it is a statin or ezetimibe where ApoB warrants it, blood pressure control, not smoking, and aerobic exercise - and none of those interact with this capsule because this capsule has no established pharmacology to interact with.
Against Vesugen: the synthetic has a defined molecule and a published in vitro endothelial dataset. Against statins, ezetimibe and antihypertensives: outcome trials in hundreds of thousands of person-years, with mortality endpoints. Against citrulline or beetroot nitrate for endothelial function: even these have flow-mediated dilation data in small human trials, which is more than Ventfort has of any kind. Against aerobic exercise: improves endothelial function measurably, and costs nothing.
Rough cost
$70–$200/month. A 20-capsule bottle covers ten to twenty days depending on dose. Indicative pricing for the branded Russian product, not verified against vendor listings in this session.
Genuinely uncertain
- No indexed primary literature exists for Ventfort under this name.
- Oral bioavailability of the peptide complex has never been measured.
- No human vascular endpoint has ever been measured for this product - not flow-mediated dilation, not blood pressure, not endothelin-1, not intima-media thickness.
- The endothelial claims are transferred from in vitro work on a different molecule delivered by a different route.
- Composition is not published lot by lot.
- Cost figures are indicative estimates and were not verified against live vendor listings in this session.
Papers
- Molecular aspects of vasoprotective peptide KED activity during atherosclerosis and restenosis Kozlov KL, Bolotov II, Linkova NS, Drobintseva AO, Khavinson VK, Dyakonov MM, Kozina LS, Advances in Gerontology, 2016 · PMID 28539025
The in vitro endothelial work on the synthetic counterpart Vesugen. This is the nearest evidence to Ventfort that exists, and it is a different molecule by a different route.
- Peptide bioregulation of aging: results and prospects Anisimov VN, Khavinson VKh, Biogerontology, 2010 · PMID 19830585
The programme overview covering the tissue-specific extracts.